의약품 임상시험 수탁기관(CRO) 서비스 시장 : 시장 규모, 점유율 및 성장률, 산업 분석 - 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of Contract Research Organization (CRO) services Market

The global Contract Research Organization (CRO) services market size was valued at USD 92.27 billion in 2025 and is projected to grow to USD 99.87 billion in 2026, reaching USD 199.28 billion by 2034, expanding at a CAGR of 9% during the forecast period (2026-2034). North America dominated the CRO services market with a 50.10% market share in 2025, supported by a strong presence of large CRO firms, high clinical trial activity, and substantial pharmaceutical R&D investments.

Contract Research Organizations provide outsourced research services including early-phase development, clinical trials, laboratory testing, regulatory support, and data management to pharmaceutical, biotechnology, and medical device companies. Increasing outsourcing of R&D activities and rising complexity of drug development pipelines are major contributors to the market's steady expansion.

Market Drivers

The growing number of clinical trials globally is a primary driver of CRO services demand. According to the World Health Organization, 38,788 clinical trials were registered worldwide in 2024, rising significantly from 28,432 trials in 2010, indicating expanding research activity. Drug development remains highly expensive, with average clinical phase costs estimated at USD 4.0 million for Phase I, USD 13.0 million for Phase II, and USD 20.0 million for Phase III. Furthermore, only 12% of drug candidates entering clinical trials receive regulatory approval, making outsourcing to CROs a cost-efficient and risk-reducing strategy, especially for small and mid-sized biopharmaceutical firms.

Partnerships between CROs and biotech companies continue to increase. In November 2024, Novotech partnered with Beijing Biostar Pharmaceuticals to strengthen clinical development programs, highlighting the growing trend of global collaborations to accelerate development timelines.

Market Restraints

Stringent and region-specific regulatory frameworks pose challenges for CRO operations. Regulatory delays in ethical approvals, site authorization, and patient recruitment slow trial initiation and increase operational complexity. According to research published by NCBI, regulatory delays are among the primary reasons for postponed clinical study timelines and recruitment difficulties, limiting faster execution of trials across multiple countries.

Market Opportunities

Emerging research in under-studied therapeutic areas such as congenital anomalies and perinatal conditions offers strong future opportunities. WHO data shows that in 2024, only 328 clinical trials targeted congenital anomalies, compared to 5,306 trials for malignant neoplasms, indicating untapped research segments. Increasing funding and cross-border collaborations are expected to expand CRO involvement in these specialized areas. In March 2021, Natera Inc. collaborated with Tesis Labs to enhance genetic testing capabilities, reflecting rising demand for specialized diagnostic research services.

Market Challenges

Regulatory heterogeneity across regions increases compliance costs and requires CROs to maintain diverse regulatory expertise. Rising cybersecurity threats also restrict patient participation in trials due to stricter data protection laws. Additionally, shortages of skilled clinical research professionals and growing infrastructure costs increase service delivery expenses and operational risks for CRO providers.

CRO Services Market Trends

Outsourcing of clinical trials continues to rise due to escalating R&D expenditure. According to EFPIA, pharmaceutical R&D spending reached USD 46,792.8 million in 2022, showing a 7.2% increase year-on-year. Companies increasingly rely on CROs to manage complex trials, rare disease research, oncology programs, and post-marketing surveillance studies.

AI and machine learning tools are being adopted for patient recruitment optimization, protocol design, predictive analytics, and trial monitoring. Decentralized clinical trials using remote monitoring, wearable devices, and digital platforms are also gaining adoption, improving patient participation and lowering site costs. Personalized medicine research supported by genomic and biomarker-based studies further increases demand for specialized CRO services.

Segmentation Analysis

By Type

The market is segmented into early phase development services, clinical services, laboratory services, and others. Early phase development services dominated the market, driven by increased focus on discovery, preclinical studies, and Chemistry, Manufacturing, and Controls (CMC) services. The clinical services segment, including Phase I-IV trials, is expected to witness strong growth due to expanding mid-stage and late-stage pipelines.

By Application

Oncology dominated application segments due to rising cancer incidence and increasing oncology drug pipelines. In the U.S., 1,958,310 new cancer cases were reported in 2023, reflecting continuous need for oncology trials. Neurology is expected to grow steadily due to increasing prevalence of Alzheimer's disease and neurodegenerative disorders, while infectious disease and metabolic disorder research also contributes to trial volume growth.

By End-User

Pharmaceutical and biotechnology companies accounted for the largest share due to rising pipeline complexity and increasing outsourcing of development stages. Medical device companies are expected to grow at a faster pace, supported by rising numbers of registered device-based clinical trials.

Regional Outlook

North America led the market with USD 49.88 billion in 2026, supported by the U.S. accounting for USD 44.78 billion in 2026. Approximately 30% of all global clinical trials are registered in the U.S. Europe ranked second with USD 25.77 billion in 2026, supported by strong pharmaceutical R&D investment. Asia Pacific is the fastest-growing region, valued at USD 19.45 billion in 2026, driven by cost advantages, rising manufacturing capabilities, and expanding CRO partnerships. China reached USD 5.69 billion, India USD 3.86 billion, and Japan USD 3.50 billion in 2026.

Competitive Landscape

Key players including IQVIA, ICON plc, Syneos Health, Charles River Laboratories, Parexel, Thermo Fisher Scientific, Medpace, and Fortrea focus on service expansion, digital integration, and global delivery models. Strategic partnerships, acquisitions, and technology investments remain central strategies for market positioning and long-term service scalability.

Conclusion

The Contract Research Organization (CRO) services market is positioned for strong long-term expansion, growing from USD 92.27 billion in 2025 to USD 99.87 billion in 2026, and further reaching USD 199.28 billion by 2034, supported by a 9% CAGR during 2026-2034. Market growth is driven by the rising number of global clinical trials, increasing R&D costs, low drug approval success rates, and the growing reliance of pharmaceutical, biotechnology, and medical device companies on outsourced research models. North America continues to lead with a 50.10% share in 2025, while Asia Pacific shows the fastest growth momentum due to cost efficiencies and expanding research infrastructure. Technological adoption such as AI-driven trial management, decentralized clinical trials, and personalized medicine research is reshaping service delivery models, while regulatory complexity and workforce shortages remain key operational challenges. Overall, CROs are becoming integral partners across the drug and device development lifecycle, playing a critical role in accelerating innovation, improving trial efficiency, and supporting global therapeutic advancement.

Segmentation By Type

• Early Phase Development Services
  • Chemistry, Manufacturing and Controls (CMC)
  • Preclinical Service
  • Discovery
• Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
• Laboratory Services
• Others

By Application

• Oncology
• Neurology
• Cardiology
• Infectious Disease
• Metabolic Disorder
• Renal/Nephrology
• Others

By End-user

• Pharmaceutical & Biotechnological Companies
• Medical Device Companies
• Academic & Research Institutes
• Others

By Region

• North America (By Type, Application, End-user, and Country)
  • U.S.
  • Canada
• Europe (By Type, Application, End-user, and Country/Country-Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Application, End-user, and Country/Country-Sub-region )
  • Japan
  • China
  • India
  • Australia & New Zealand
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Rest of the World (By Type, Application, and End-user)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Number of Clinical Trials Conducted by Key Countries/ Regions, 2025
• 4.2. Distribution of Clinical Trials, 2025
• 4.3. Overview: Start-ups and Innovations in the Contract Research Organization (CRO) Services Market
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Contract Research Organization (CRO) Services Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Early Phase Development Services
    • 5.1.1.1. Chemistry, Manufacturing and Controls (CMC)
    • 5.1.1.2. Preclinical Services
    • 5.1.1.3. Discovery
  • 5.1.2. Clinical
    • 5.1.2.1. Phase 1
    • 5.1.2.2. Phase 2
    • 5.1.2.3. Phase 3
    • 5.1.2.4. Phase 4
  • 5.1.3. Laboratory Services
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Oncology
  • 5.2.2. Neurology
  • 5.2.3. Cardiology
  • 5.2.4. Infectious Disease
  • 5.2.5. Metabolic Disorders
  • 5.2.6. Renal/Nephrology
  • 5.2.7. Others
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Pharmaceutical & Biotechnological Companies
  • 5.3.2. Medical Device Companies
  • 5.3.3. Academic & Research Institutes
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America Contract Research Organization (CRO) Services Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Early Phase Development Services
    • 6.1.1.1. Chemistry, Manufacturing and Controls (CMC)
    • 6.1.1.2. Preclinical Services
    • 6.1.1.3. Discovery
  • 6.1.2. Clinical
    • 6.1.2.1. Phase 1
    • 6.1.2.2. Phase 2
    • 6.1.2.3. Phase 3
    • 6.1.2.4. Phase 4
  • 6.1.3. Laboratory Services
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Oncology
  • 6.2.2. Neurology
  • 6.2.3. Cardiology
  • 6.2.4. Infectious Disease
  • 6.2.5. Metabolic Disorders
  • 6.2.6. Renal/Nephrology
  • 6.2.7. Others
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Pharmaceutical & Biotechnological Companies
  • 6.3.2. Medical Device Companies
  • 6.3.3. Academic & Research Institutes
  • 6.3.4. Others
• 6.4. Market Analysis - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Contract Research Organization (CRO) Services Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Early Phase Development Services
    • 7.1.1.1. Chemistry, Manufacturing and Controls (CMC)
    • 7.1.1.2. Preclinical Services
    • 7.1.1.3. Discovery
  • 7.1.2. Clinical
    • 7.1.2.1. Phase 1
    • 7.1.2.2. Phase 2
    • 7.1.2.3. Phase 3
    • 7.1.2.4. Phase 4
  • 7.1.3. Laboratory Services
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Oncology
  • 7.2.2. Neurology
  • 7.2.3. Cardiology
  • 7.2.4. Infectious Disease
  • 7.2.5. Metabolic Disorders
  • 7.2.6. Renal/Nephrology
  • 7.2.7. Others
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Pharmaceutical & Biotechnological Companies
  • 7.3.2. Medical Device Companies
  • 7.3.3. Academic & Research Institutes
  • 7.3.4. Others
• 7.4. Market Analysis - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia pacific Contract Research Organization (CRO) Services Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Early Phase Development Services
    • 8.1.1.1. Chemistry, Manufacturing and Controls (CMC)
    • 8.1.1.2. Preclinical Services
    • 8.1.1.3. Discovery
  • 8.1.2. Clinical
    • 8.1.2.1. Phase 1
    • 8.1.2.2. Phase 2
    • 8.1.2.3. Phase 3
    • 8.1.2.4. Phase 4
  • 8.1.3. Laboratory Services
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Oncology
  • 8.2.2. Neurology
  • 8.2.3. Cardiology
  • 8.2.4. Infectious Disease
  • 8.2.5. Metabolic Disorders
  • 8.2.6. Renal/Nephrology
  • 8.2.7. Others
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Pharmaceutical & Biotechnological Companies
  • 8.3.2. Medical Device Companies
  • 8.3.3. Academic & Research Institutes
  • 8.3.4. Others
• 8.4. Market Analysis - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. South Korea
  • 8.4.6. Southeast Asia
  • 8.4.7. Rest of Asia Pacific

9. Rest of the World Contract Research Organization (CRO) Services Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Early Phase Development Services
    • 9.1.1.1. Chemistry, Manufacturing and Controls (CMC)
    • 9.1.1.2. Preclinical Services
    • 9.1.1.3. Discovery
  • 9.1.2. Clinical
    • 9.1.2.1. Phase 1
    • 9.1.2.2. Phase 2
    • 9.1.2.3. Phase 3
    • 9.1.2.4. Phase 4
  • 9.1.3. Laboratory Services
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Oncology
  • 9.2.2. Neurology
  • 9.2.3. Cardiology
  • 9.2.4. Infectious Disease
  • 9.2.5. Metabolic Disorders
  • 9.2.6. Renal/Nephrology
  • 9.2.7. Others
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Pharmaceutical & Biotechnological Companies
  • 9.3.2. Medical Device Companies
  • 9.3.3. Academic & Research Institutes
  • 9.3.4. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Medpace
  • 10.2.2. Laboratory Corporation of America Holdings
  • 10.2.3. ICON plc
  • 10.2.4. IQVIA Inc
  • 10.2.5. Syneos Health
  • 10.2.6. Novotech
  • 10.2.7. KCR S.A.
  • 10.2.8. PSI
  • 10.2.9. Ergomed Group
  • 10.2.10. Thermo Fisher Scientific Inc.
  • 10.2.11. WuXi Biologics
  • 10.2.12. Tigermed
  • 10.2.13. Worldwide Clinical Trials
  • 10.2.14. Charles River Laboratories
  • 10.2.15. Microbiologics
  • 10.2.16. Parexel International (MA) Corporation